Screener
Kymera Therapeutics KYMR Cash Flow Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| -$132M-60.6% | -$61.21M+20.1% | -$69.23M-5.6% | -$86.98M-22.9% | -$82.18M-31.5% | ||
| $2.02M-5.9% | $2.03M-2.6% | $2.02M-1.3% | $2.03M+2.3% | $2.15M+8.2% | ||
| $18.84M+19.2% | $18.94M+22.8% | $16.01M+12.5% | $14.45M+4.7% | $15.8M+6.0% | ||
| -$77.91M-187% | -$54.07M+9.7% | -$88.84M-12.2% | -$66.75M-8.0% | -$27.11M+46.0% | ||
| $315K+74.0% | $473K-31.9% | $434K-7.1% | $106K-88.7% | $181K— | ||
| —— | —— | -$142.84M-394% | -$394.4M— | -$235.3M-49.2% | ||
| $225.57M+471% | $14.42M-94.1% | $18.77M+7,175% | $705.22M+25,405% | $39.51M-84.3% | ||
| $249.28M+212% | -$19.6M-108% | -$212.91M-603% | $244.07M+2,456% | -$222.9M-618% | ||
| -$78.23M-187% | -$54.54M+10.0% | -$89.27M-12.1% | -$66.85M-6.6% | -$27.29M+45.4% |
FAQ
- How much cash does Kymera Therapeutics generate?
- Kymera Therapeutics (KYMR) generated -$287.6M in operating cash flow over the trailing twelve months.
- What is Kymera Therapeutics's free cash flow?
- After $1.3M of capital expenditures, Kymera Therapeutics's free cash flow was -$288.9M over the trailing twelve months, down 25.5% year over year.
- Where does Kymera Therapeutics's cash flow data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
